Actively Recruiting
Phase II Study of Zanidatamab with Pembrolizumab and Chemotherapy for Untreated HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma
Led by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Updated on 2026-06-30
80
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of zanidatamab, pembrolizumab, and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma GEA who have not received prior palliative treatment. This phase II trial focuses on patients whose tumors test positive for HER2 and PD-L1. The study aims to estimate treatment effectiveness and explore molecular markers that might predict response, toxicity, and survival. Participants receive zanidatamab intravenously every 2 weeks, pembrolizumab intravenously every 6 weeks, and a chemotherapy regimen called modified FOLFOX every 2 weeks. The trial is a single-arm, open-label study conducted at approximately 30 sites in Germany and Austria, enrolling about 80 patients. During the study, participants are monitored for treatment efficacy, safety, tolerability, and quality of life. Researchers conduct laboratory tests, imaging, and clinical assessments up to 42 months. The main outcome is treatment efficacy measured 12 months after starting medication, with ongoing evaluations of side effects and quality of life. The total participation time may extend up to 42 months, including follow-up assessments.
CONDITIONS
Brief Title
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
Research Team
A
Alexander Stein, Prof. Dr.
C
Clara Dreyling, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here